Gene Therapy in Parkinson's Disease
Ph Hantraye’ Conference at the Mediatheque of Fontenay aux Roses
Ph Hantraye’ Conference at the Mediatheque of Fontenay aux Roses
Memory and epilepsy: the role of connexin 30
CEA-I2BM shows that connexin 30 is a new potential therapeutic target to increase memory or reduce seizures in patients with epilepsy.
"Connexin 30 sets synaptic strength by controlling astroglial invasion synapse" in Nature Neurosciences
Parkinson's disease: a breakthrough thanks to gene therapy
A Franco-British team (AP-HP, INSERM, UPEC, CEA / MIRCen, Oxford Biomedica, Cambridge University) conducted a Phase I-II gene therapy clinical trial in patients with an advanced form of Parkinson’s disease.
MIRCen, preclinical research platform on neurodegenerative diseases located in Fontenay-aux-Roses, has just acquired a new Magnetic resonance imaging (MRI) scanner dedicated to rodents.
Kick off Meeting de NeurATRIS, Infrastructure de Recherche Translationnelle pour les Biothérapies en Neurosciences
Kick off Meeting de NeurATRIS